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Background: Numerous explanatory randomized trials support the efficacy of chronic disease interventions,
including smoking cessation treatments. However, there is often inadequate adoption of these interventions for
various reasons, one being the limitation of generalizability of the explanatory studies in real-world settings.
Randomized controlled trials can be rated as more explanatory versus pragmatic along 10 dimensions. Pragmatic
randomized clinical trials generate more realistic estimates of effectiveness with greater relevance to clinical practice
and for health resource allocation decisions. However, there is no clear method to scale each dimension during the
trial design phase to ensure that the design matches the intended purpose of the study.
Methods: We designed a pragmatic, randomized, controlled study to maximize external validity by addressing
several barriers to smoking cessation therapy in ambulatory care. We analyzed our design and methods using the
recently published ‘Pragmatic–Explanatory Continuum Indicatory Summary (PRECIS)’ tool, a qualitative method to
assess trial design across 10 domains. We added a 20-point numerical rating scale and a modified Delphi process to
improve consensus in rating these domains.
Results: After two rounds of review, there was consensus on all 10 domains of study design. No single domain was
scored as either fully pragmatic or fully explanatory; but overall, the study scored high on pragmatism.
Conclusions: This addition to the PRECIS tool may assist other trial designers working with interdisciplinary
co-investigators to rate their study design while building consensus.
Keywords: Clinical trial, Explanatory, Pragmatic, Smoking cessation, PRECIS, Varenicline, Bupropion,
Nicotine replacement therapyBackground
Schwartz and Lellouch [1] first used the terms ‘pragmatic’
to describe trials designed to help choose between options
for therapy, and ‘explanatory’ to describe trials designed to
test causal research hypotheses – for example, whether a
particular intervention causes a specific biological effect.
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reproduction in any medium, provided the orare largely explanatory are necessary to establish the safety
and efficacy of new interventions and to inform evidence-
based guidelines [2]. However, explanatory trials for
chronic diseases such as hypertension, diabetes, de-
pression and addiction have a number of limitations [3,4].
They are often conducted in tertiary centres, exclude
people with comorbid conditions that cluster with the
condition of interest, provide some incentive for participa-
tion, and mandate intensive follow-up visits and contact
with research staff [5].
Explanatory studies, although highly internally valid, are
often less generalizable to outpatient community settings.
There has been a call for more real-world ‘practical’ ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rudimentary methods for distinguishing between efficacy
(explanatory) and effectiveness (pragmatic) studies have
been employed [1,3,4,6-8]. The definition and design of
pragmatic trials vary considerably, and are derived mainly
from descriptive papers. These often describe observa-
tional studies that, in spite of limitations in internal vali-
dity and the ability to control for confounders, have
frequently been used to influence clinical practice [9,10].
Health policy makers have to make resource allocation
decisions based on cost-effectiveness studies that may
have excluded various populations of interest [3,11].
Therefore, randomized clinical trials with inherent internal
validity, but with greater ecological and external validity –
pragmatic, randomized trials – are required in real-world
settings after safety and efficacy have been established.
In Canada, there is limited drug plan coverage for smo-
king cessation treatments despite their proven efficacy
[12-15], ostensibly due to the lack of pragmatic, rando-
mized trials. The multicentre, community-based, prag-
matic, randomized, controlled ACCESSATION Study
(ClinicalTrials.gov Identifier NCT00818207) was designed
to determine whether smoking cessation treatment insu-
rance coverage is associated with improved outcomes in
clinical practice. We addressed two key barriers to smo-
king cessation treatment: i) the lack of formulary coverage
for smoking cessation treatment by most governments
and private drug plans in Canada (excepting the province
of Quebec at the time of the study), and ii) the cost of
medications to patients. Based on existing study design
elements that favoured a pragmatic study design, we
developed the study protocol to make the design as prag-
matic as possible. The basic study flow (Figure 1) resem-
bles that of a traditional randomized, controlled trial.
However, for each aspect of the trial, we attempted to
simulate real-world conditions; this was based on discus-
sion among the authors.
After our study was initiated, an international consor-
tium published the PRECIS (Pragmatic–Explanatory
Continuum Indicator Summary) [16] model to help tri-
alists assess the degree to which a study design falls
along the pragmatic–explanatory continuum. The tool
uses 10 key domains that qualitatively distinguish prag-
matic (externally valid) from explanatory (internally
valid) trials [16]. Although it has not been validated to
predict outcomes post facto, no other instrument existed
at the time and the consortium that developed this tool
invites validation and enhancements to the process.
Other limitations included the absence of a quantitative
rating system that would increase precision, reproduci-
bility and comparability of scores and of a formal
process to reach consensus among investigators.
This paper describes the use of the PRECIS tool,
coupled with the use of a numerical scale and a modifiedDelphi technique, to achieve consensus on the trial de-
sign, to characterize aspects of the study that determine
whether it could be described as pragmatic.
Methods
The 50 participating sites of the ACCESSATION Study
that could utilize a Central Ethics Committee were
reviewed and approved by Institutional Review Board
(IRB) Services (Suite 300, 372 Hollandview Trail, Aur-
ora, ON L4G 0A5, Canada), and the seven remaining
sites submitted to an IRB that reviewed and approved
the study in the respective regions.
We analysed the ACCESSATION Study trial design
elements on a continuum using the qualitative, multidi-
mensional PRECIS tool. Table 1 provides an overview of
the most important study design characteristics in rela-
tion to the 10 domains of the PRECIS tool, and was
developed by the primary author.
Domain rating process
To simplify the rating process, we added a quantitative
aspect to evaluations using the PRECIS tool by adding a
visual 20-point numerical scale, where 1 represented ‘en-
tirely explanatory’ and 20 represented ‘entirely prag-
matic’. Six raters (five authors and one consultant: one
academic family physician with an interest in smoking
cessation; one cardiac rehabilitation physician with ex-
pertise in pharmacoeconomics; one addiction medicine
physician and clinical scientist with a focus on tobacco
dependence; one pharmacist with expertise in pharma-
coeconomics; one pharmacologist with clinical research
and medical affairs experience in the pharmaceutical in-
dustry; and one consultant physician with pharmacoeco-
nomic and policy advice experience in Quebec) were
requested to score the trial on each domain in Table 1
according to where they believed it fell on a pragmatic–
explanatory trial continuum, and to provide an explan-
ation for their decision. Raters were asked to review
Table 1 and to read the manuscript: ‘A pragmatic–
explanatory continuum indicator summary (PRECIS): a
tool to help trial designers’ [16] as a guide to scoring the
10 domains of the ACCESSATION Study. A modified
Delphi technique was then used to ensure a common
understanding among the raters, given their multidiscip-
linary background (addiction medicine, family medicine,
internal medicine, pharmacy, pharmacoeconomics):
1. Initial group discussion among the raters regarding the
study protocol and various elements classified by the 10
domains and criteria to justify their position, on a scale
of 1 to 20 along the explanatory–pragmatic continuum.
2. Round 1 scoring: raters independently scored each
domain (see domain rating process below); an
independent assistant collated the scores and
Full SCT coverage (100%)
Pre-screening
period
Week 0 2 52
V1 T2
13* 26 39*












point prevalence of abstinence
at Week 26
*Other abstinence assessments were conducted at Weeks 13 and 39 (other secondary endpoints)






between Weeks 26 and 52
Key secondary endpoint
Urine cotinine test-confirmed
7-day point prevalence of
abstinence at Week 26
Target quit date
Figure 1 ACCESSATION study design.
Selby et al. BMC Medical Research Methodology 2012, 12:101 Page 3 of 13
http://www.biomedcentral.com/1471-2288/12/101developed descriptive statistics (median, mean,
standard deviation [SD]). The results were
anonymized before the face-to-face group
discussion.
3. A second face-to-face group discussion among the
raters was held to clarify individual ratings, gain a
better understanding of each domain and reach
consensus.
4. Round 2 scoring: raters did a second round of rating
independently and submitted their scores. Scores
were again collated in an anonymized manner to
generate descriptive statistics (Figure 2A). The
results of the first and second rounds of scoring
were plotted in a spider graph as described by the
PRECIS tool developers [16] (Figure 2B).
Results
Table 1 results, developed prior to the group discus-
sions and domain rating process, suggested that only
the domain related to ‘Follow-up intensity’ was consid-
ered more explanatory than pragmatic. Domains related
to ‘Primary trial outcome’, ‘Secondary trial outcome’ and
‘Practitioner adherence to study protocol’ were consid-
ered to have a balance of both pragmatic and expla-
natory elements. However, the descriptive statistics
calculated after ratings and discussions had taken place(Figure 2A) indicated that all 10 domains scored higher
than the midpoint of 10.5. This indicates that all
the domains were more pragmatic than explanatory –
albeit some were borderline. Descriptive statistics
(Figure 2A) indicated that there was less variation in
scores after the second round than after the first round
of discussions for every domain. This suggests that the
raters’ opinions converged, presumably as a result of
reaching a common understanding of all aspects of the
trial in relation to each of the PRECIS domains. The
spider plot (Figure 2B) demonstrates the shift in opi-
nions among the raters between the first to the second
round of discussions, with the plot becoming larger –
more pragmatic – after the second round of
discussions.
Discussion
This paper describes the use of the PRECIS tool for the
multidimensional evaluation of the ACCESSATION
Study, and provides a thorough exploration of the study
design that impacts its pragmatic/explanatory nature.
Use of the tool highlighted study design features for
which discrepancy of opinion existed among the authors
regarding the degree of pragmatism within the trial, and
provided a basis for discussing those areas more ex-
plicitly. However, this occurred after the study was
Table 1 Pragmatic and explanatory approaches in the ACCESSATION study
PRECIS domain Favours pragmatic trial Criteria that do not
favour either
Favours explanatory trial Summary
Participants
Eligibility criteria • Adult smokers
(aged 18–75 years)
• Prospective subjects were
motivated to make a quit
attempt within 14 days
• Subjects were recruited
from community-based
sites across Canada
• Comorbid patients included
• Past compliance
not considered
• No risk stratification
• Smokers excluded if
they have existing SCT;
female subjects of
childbearing potential
could be included if not
pregnant or nursing, and
practising effective
contraception
(not eligible for within-label
pharmacotherapy due to
safety reasons)
• Smokers excluded if
they had a quit attempt
in the past 30 days, had
unstable comorbid conditions,






≥10 cigarettes per day
• Eligibility had to
be determined







• Physicians and patients controlled
the type of smoking cessation
interventions according
to usual practice Any on-label
combination of non- and
pharmacological intervention
was permitted
• Participants could switch
medications
• Type or number of
co-interventions used was not limited
• Drug reimbursement card allowed any
pharmacist to fill the prescription,
rather than the doctor’s office
• Side effects were to be managed
at the discretion of the provider
• Fewer contact minutes than efficacy
trials with allowance for as-needed
visits to assist the smoker
• Following randomization,
a participant could not be
re-randomized to a more
favourable arm
• Provision of the card by
the practitioner is not how
insurance coverage cards are
provided to patients
• x`More contact









• All physicians were







• Most investigators (80%) had
no prior clinical research experience
• Primarily treatment- seeking patients
from physician practice (93%)
• None of the authors were
associated with sites of recruitment








• Participants received counselling
about smoking cessation options
and chose their SCT prior
to randomization.
This reflects usual practice
• Participants were given a drug
reimbursement card,
which included
$5 to partially offset
pharmacist dispensing fees,
to enable tracking
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• Randomization was at
the patient level to mimic the
real world, so that within the same
practice some smokers received
reimbursement while others did not.
Practitioner expertise was therefore




• Given the central
randomization process,
re-randomization
to a more favourable arm
(i.e., SCT coverage) was not possible
• Some training of smoking
cessation occurred at the
investigator meeting









• Participants did not attend
the clinic on a weekly basis
• At clinic visits/telephone contact,
outcomes were measured,
and AEs and
method(s) used to quit
(if any) were recorded
• No exhaled CO levels
were measured to
reflect real-world practice
• Randomization visit involved
more procedures than would
usually be included at the first
visit to discuss quitting







practice to balance the
needs of data
collection with the clinical reality of
access to care
• Strong focus on measuring
outcomes and AEs
from SCT use and/or quitting















the full and no
reimbursement groups
at Week 26 as
opposed to 4 weeks
continuous abstinence
in efficacy trials in smoking
cessation from
the quit date. This endpoint is used in
observational studies in
telephone quitline
and NRT distribution studies
• Outcome assessed locally and
no central adjudication of outcome
• Scheduled time for
assessment of







• A key secondary endpoint
was self-reported 7-day point
prevalence of abstinence
at Week 26, confirmed by
urine cotinine analysis.
Urine collection is common in practice
and the least intrusive
method to confirm self-reports
• Exhaled CO was not used,
since this is less real-world practice
• Urine cotinine confirmation was
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• Once randomized, participants could
choose to use (or not) any
currently available SCT
• SCT use patterns were
passively measured by
drug reimbursement
card use across both groups
• Data regarding adherence
were collected but not shared
with prescribers
• All or a portion of the participants
were compensated for costs incurred
to visit the clinic. They could have
been compensated between $25 and
$50 for each on-site visit (four on-site
visits at V1, V4, V7 and V10).
There was variation between
some sites with the total allocation







• There was no measure of how
practitioners provided SCT per se or
developed their source documentation
for the study






who were not motivated to quit
• Sites and physicians were visited by
the site monitor twice during the
study but kept to a minimum
• Randomization was centrally
controlled to prevent gaming.
However, participants could use
any available SCT
• Standard study auditing
processes discovered
one site was not compliant with GCP
(inadequate source documentation)
• Study monitors would bring
off-label use of medication to the









• The main analysis will be the ITT
population post-randomization regardless
of use of the drug reimbursement card
or making a quit attempt, with missing
data being counted as being a smoker
• Mostly
pragmatic
AE: adverse event; CO: carbon monoxide; GCP: good clinical practice; GP: general practitioner; FP: family practitioner; ITT: intent-to-treat; NRT: nicotine replacement
therapy; SCT: smoking cessation treatment.
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high variability in ratings at the first scoring round was
primarily due to differences in interpretation of the cri-
teria described in the PRECIS tool and of how the design
elements of the study fitted these dimensions. The
dimensions were discussed and ratings were clarified
based on the PRECIS tool. Therefore, it appears that
deliberate discussion about each dimension is neces-
sary, especially when there is considerable variability
between raters. Use of a Delphi method is appropriate
to reach consensus on such complex and subjective
material.
If we were to design the study to be more pragmatic,
we would reduce the frequency of visits for assessments
and use a patient- and physician-defined primary out-
come measure. For example, we would ask patients if
they had quit or not, as opposed to using a validated
scale. To make the study completely pragmatic on the
primary outcome measure, we would use an administra-
tive database to see if there was reduction in healthcare
utilization in those who received coverage versus the
control group.
Developers of the PRECIS tool [16] considered it to be
an initial attempt to identify and quantify trial character-
istics that distinguish between pragmatic and explanatorytrials, and requested suggestions for its further develop-
ment. Since 2010, five papers describing modifications
to the PRECIS tool have been published, all of which
employ quantification of the ratings on each dimension
[17-21]. Each paper is summarized in Table 2.
In a similar analysis to ours, Riddle et al. used the
PRECIS tool to design a randomized, controlled trial
of pain-coping skills [17]. The authors also used the
PRECIS tool to assist with face-to-face meetings and
found the approach helpful, for similar reasons. They,
too, added a semi-quantitative scale, but of 4 cm in
length, and had three rounds of discussions. Their
final evaluation led to greater agreement on all dimen-
sions, whereby they increased the explanatory scores
of each domain. The timing of their exercise
prompted the authors to make revisions to the design
of their randomized trial prior to submission for fund-
ing [17].
Tosh et al. [19] had three reviewers (co-authors) use a
1- to 5-point scale to review published trials in mental
health; they referred to this as the Pragmascope. If a di-
mension could not be rated, it received a score of 0.
Each trial could be allocated a total possible score of 50,
with a range of 0 to 30 indicating an explanatory trial,






















































































Figure 2 A. Author ratings for the ACCESSATION trial: median scores (min, max). B. Author ratings for the ACCESSATION trial using the
pragmatic–explanatory continuum indicator summary (PRECIS).
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Table 2 Studies attempting to quantify PRECIS dimensions since 2010


















Riddle et al. 2010 [17] •Prospective use of
the tool to modify
study design in 3-arm
study of pain coping in
patients scheduled to have
a knee replacement 1-day
meeting of 7
authors/investigators:
1) Pre-read Thorpe et al., 2009
2) Discuss goal of study
3) Discuss criteria
4) Initial blinded rating
5) Ideal blinded rating
6) 3rd rating to see if
consensus was reached





























Bratton et al. 2011 [18] • Retrospective
• 2 reviewers rated
3 published studies on
TB treatment
and discussed
how to rate them on
each dimension
• No, but modification
to the dimensions made
(practitioner
expertise) combined
and a new spoke
for blindness
inserted









































• 1 to 5; 0 for missing
information
• Total score, 0 to 50
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Table 2 Studies attempting to quantify PRECIS dimensions since 2010 (Continued)
(total score >35)














weight loss in obese
patients with
comorbid conditions.







care in those with
one CVD risk factor.
Studies were ongoing
and in the field
• 9 reviewers scored each
protocol in a
4-step process.
1) Read article and review
webinar by Sackett
2) Score using 0 to
4 on the dimension









with the primary care
practices














• ? Rater bias
towards pragmatic
• Scale difficult to
interpret, but
need cognitive testing
as part of a
qualitative study
















• Modified the PRECIS
tool (called
PRECIS Review tool
[PR tool]) to grade
individual
trials and systematic
• 1 to 5 rating
• Individual
studies and the
review itself were scored
• Abandoned VAS
with 0 to




• Used a Likert-type


























































• 2 systematic reviews
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5, with concurrent %
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Tosh et al use ranges of 0 to 16 to describe explanatory
trials and 16 to 35 to describe an interim trial that is
balanced. They had independent ratings and averaging
of scores, but did not describe an explicit process to be
used to reach consensus.
Several limitations are associated with the use of the
Pragmascope at this time. For example, if the dimension
could not be rated, the dimension would receive a score
of 0 and as such, bias ratings towards the study being
explanatory. Moreover, the use of cut-offs for the total
scores categorizing trials reverts to the problem of look-
ing at trial design as purely explanatory or pragmatic
[8,16]. Moreover, the reason for the cut-offs used is
not specified. It is not clear why they did not choose
25 (the midpoint) to indicate a balanced trial and any
score less than that would favour an explanatory study,
while any score greater than 25 would favour a pragmatic
study. Moreover, we agree with Glasgow et al. [5] and
Spigt and Kotz [22] that composite scores should be
avoided because widely disparate trials can receive the
same score and defeat the purpose of having a dimensional
approach to the rating.
The PRECIS Review (PR) tool was developed by
Koppenaal et al. [21] to evaluate systematic reviews and
the randomized controlled trials used in the review to
help policy makers decide on applicable trials to in-
form their work. Like us, they quickly realised that a
Visual Analog Scale (VAS) scale of 0 to 10 was arbitrary
and so converted it to a Likert-type scale of 1 to 5, also in-
cluding a percentage score. They used two reviewers and
an additional reviewer to rate the score when consensus
could not be reached. The scoring scale appeared to be
valid for the stated purpose and they acknowledged the
limitations of broader applicability. Again, given the pur-
pose behind the PRECIS tool to introduce multidimen-
sionality to the evaluation of a study design, scores are
important to initiate and guide discussion, but broader
consensus on the rating is still required to inform decision
making.
Glasgow et al. [20] also used a 5-point (0 to 4) scale to
rate three interrelated, yet separate studies by investiga-
tors from three separate institutions. They describe a
similar process of training reviewers and noted that
investigators tended to rate their own papers as being
pragmatic. The scoring revealed moderate levels of
variability with most variability within 1 point on the
5-point scale. However, several telephone calls were
required to develop consensus on the meaning of each
score. It is possible that the scale was not sufficiently
sensitive to detect a difference, which would be import-
ant if the group was interested in achieving consensus,
but less so if trying to evaluate the study per se and
categorize the protocol dichotomously.Our proposed refinement also identified the need for a
rating scale, but included a modified Delphi technique
to reach consensus [23]. We chose a 20-point numerical
scale to approximate a continuous scale. This permitted
easier, more accurate and more stable coding of the re-
sponse using e-mail. A VAS with measurement is appro-
priate when standardized in pen and paper format rather
than e-mail, which distorts the dimensions. We also
used extreme anchor points, 1 to 20, to discourage rat-
ing the domains beyond the numbers provided. More-
over, Likert scales have increased reliability with up to
11 steps, 7 steps being the minimum. Therefore, the
scale we used was most sensitive to capture inter-
individual differences to better target our discussions.
This may be one reason why the spider graphs do not
reach the extremes, but it is also possible that the raters
appreciated that elements existed in each dimension to
prevent an extreme rating. Use of the iterative technique
provided a sound basis for discussing the intricacies of
the trial design and allowed individuals to provide view-
points anonymously and then offer their opinions during
face-to-face meetings.
Taken together, these examples demonstrate that de-
pending on the purpose of the application of the PRECIS
tool (study evaluation versus study design), different
scales and methods may need to be used to rate studies.
However, our method may be particularly helpful to tri-
alists to ensure common understanding of a study de-
sign when working in teams with disparate expertise.
Therefore, other investigative teams may find these
approaches helpful.
The multidimensional PRECIS tool can be implemen-
ted easily by investigators and represents a major ad-
vance in the design and evaluation of clinical trials that
inform practice, as demonstrated by our own experience
and that of others. All clinical trialists need to make
compromises in their design due to a variety of practical
factors that affect the conduct of a large study. Colla-
borative research by a team requires consensus on study
design to ensure the methods are appropriate to answer
the study question. Methods to evaluate study design
and reach consensus are needed to ensure that disparate
views and perspectives can be reconciled so that the best
possible course of action is adopted.
Although most agree that the 10 dimensions are ne-
cessary to understand the explanatory–pragmatic con-
tinuum, numerical scales run the risk of dichotomously
classifying the study and we did not provide a composite
score for the study. This required a qualitative approach.
Therefore, a more structured process using the Delphi
technique that we employed, or a similar nominal group
technique used by Riddle et al. [17], allowed a more
democratic process of consensus among the investigators,
who hailed from different disciplines and institutions.
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design stage of a multicentre collaborative study to resolve
disagreements and assist in reaching a common under-
standing of the design of the study.
Conclusions
The PRECIS tool may be applicable across a variety of
health-related studies to help investigators design trials
most appropriate to their study question and hypothesis.
Moreover, clinicians, study reviewers, policy makers and
the so-called post-regulatory decision-makers can use
this tool to determine if a study has generalizability to
the populations of interest and the level of reasonable
effectiveness that can be expected in different ecological
settings versus those in explanatory trials. In these situa-
tions, simpler rating systems as described by others
might be adequate to achieve the desired outcome.
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